Current Report Filing (8-k)
April 13 2023 - 5:25PM
Edgar (US Regulatory)
0000316253
false
0000316253
2023-04-06
2023-04-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of report (Date of earliest
event reported): April 6, 2023
Enzo Biochem, Inc.
(Exact Name of Registrant
as Specified in Its Charter)
New York
(State or Other Jurisdiction
of Incorporation)
001-09974 |
|
13-2866202 |
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
81 Executive Blvd. Suite 3 |
|
|
Farmingdale, New York |
|
11735 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(212) 583-0100
(Registrant’s Telephone
Number, Including Area Code)
N/A
(Former Name or Former Address,
if Changed Since Last Report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
Common Stock, $0.01 par value |
|
ENZ |
|
The New York Stock Exchange |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On April
6, 2023, Enzo Biochem, Inc. (the “Company”) experienced a ransomware attack that impacted certain information technology systems.
In response, the Company promptly deployed containment measures, including disconnecting its systems from the internet, and launched an
investigation with assistance from third-party cybersecurity experts. The Company has activated its disaster recovery plan, which allows
it to continue operations while it brings its systems back online.
On April
11, 2023, the Company became aware that certain data was extracted from the Company’s information technology systems as part of
this incident. The investigation of this incident and the assessment of its impact is ongoing.
The Company’s
facilities remain open, and it continues to provide services to its patients and partners using established back-up processes and other
downtime procedures. However, these back-up procedures can create operational challenges and have caused delays in the processing of laboratory
specimens. The Company is actively engaged in fully restoring or replacing affected systems, which is expected to be largely complete
in the coming days.
The Company
is also evaluating the extent of the incident and working diligently to mitigate its effects. The Company has incurred, and may continue
to incur, certain expenses related to this attack, including expenses to respond to, remediate and investigate this matter. Further, the
Company remains subject to risks and uncertainties as a result of the incident, including as a result of the data that was extracted from
the Company’s network as noted above.
Forward-Looking Statements
This
Current Report on Form 8-K includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions
as to future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking
statements relating to our expectations regarding our ability to contain and assess the ransomware attack and the impact of the ransomware
attack on our operations and financial results. These statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated
in these forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied include
the ongoing assessment of the ransomware attack, legal, reputational and financial risks resulting from cyberattacks, including the ransomware
attack, the effectiveness of business continuity plans during the ransomware attack, and the other factors discussed in our most recent
Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update
or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required
under applicable securities law.
Item 9.01 Financial Statements
and Exhibits.
Exhibit |
|
Exhibit Name |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC. |
|
|
|
Date: April 13, 2023 |
By: |
/s/ Hamid Erfanian |
|
|
Hamid Erfanian |
|
|
Chief Executive Officer |
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024